首页> 外文OA文献 >Topical gabapentin gel alleviates allodynia and hyperalgesia in the chronic sciatic nerve constriction injury neuropathic pain model
【2h】

Topical gabapentin gel alleviates allodynia and hyperalgesia in the chronic sciatic nerve constriction injury neuropathic pain model

机译:加巴喷丁外用凝胶减轻慢性坐骨神经收缩损伤神经性疼痛模型的异常性疼痛和痛觉过敏

摘要

Background: Systemic gabapentin is a mainstay treatment for neuropathic pain though there areudside effects. Localized therapy may curtail such side effects so a topical gabapentin dermaludapplication was examined in the chronic constriction injury (CCI) model of neuropathic pain.udMethods: Partial denervation CCI was achieved by rat sciatic nerve ligation. Gabapentin gelud(10% w/w) was applied three-times daily on the ipsilateral or contralateral plantar surface of theudhind-paw while in a concurrent systemic study, gabapentin was intraperitoneally administereduddaily (75 mg/kg) for 30 days. Tests for static- and dynamic- mechano-allodynia (paw withdrawaludthreshold [PWT] to von-Frey filament application and latency [PWL] to light brushing), coldallodyniaud(paw withdrawal duration [PWD] to acetone), heat- (PWL and PWD) and mechanohyperalgesiaud(PWD to pin-prick) were utilized to assess pain while effects on locomotion (openudfield) and motor balance (rotarod and footprint-analysis) were measured on days 5-30 postsurgery.udResults: Topical application of gabapentin gel ipsilaterally but not contralaterally alleviatedudCCI-induced static- (days 10-30) and dynamic-allodynia (days 15-30), suppressed cold-allodyniaud(days 10-30), heat- (days 15-30) and mechano-hyperalgesia (days 5-30) indicating a local action.udSystemic gabapentin exhibited similar pain profiles but was associated with motor impairment.udThe gabapentin gel formulation afforded desirable neuropathic pain alleviating effects devoid ofudunwanted systemic side-effects.udConclusions: These outcomes disclose an expedient pharmacological validation of theudeffectiveness of topical gabapentin gel against an extensive range of nociceptive stimulusudmodalities utilizing the CCI-induced neuropathic pain model. They also advocate further clinicaludstudies on topical gabapentin with regard to certain neuropathic pain syndromes.
机译:背景:全身加巴喷丁虽然有副作用,但仍是神经性疼痛的主要治疗手段。局部治疗可能会减少此类副作用,因此在神经性疼痛的慢性收缩性损伤(CCI)模型中检查了局部加巴喷丁的皮肤 ud应用。 ud方法:通过大鼠坐骨神经结扎实现部分去神经CCI。加巴喷丁凝胶 ud(10%w / w)每天3次涂在爪子的同侧或对侧足底表面,而在同时进行的全身研究中,腹膜内给予加巴喷丁 ud(75 mg / kg) 30天。测试静态和动态机械性异常性疼痛(对冯·弗雷丝应用的爪子撤回阈值[PWT],对轻刷的潜伏期[PWL]),冷性痛觉过敏 ud(对丙酮的爪撤回持续时间[PWD]),加热(PWL和PWD)和机械性痛觉过敏 ud(PWD到针刺)用于评估疼痛,​​而术后5-30天测量对运动的影响(开放 udfield)和运动平衡(rotarod和足迹分析) udResults:加巴喷丁凝胶同侧局部施用,但对侧却没有缓解 udCCI诱导的静态(10-30天)和动态异常性疼痛(15-30天),抑制冷性异常性疼痛 ud(10-30天),热刺激(第15-30天)和机械性痛觉过敏(第5-30天)表明有局部作用。 ud全身性加巴喷丁显示相似的疼痛特征,但与运动障碍有关。 ud加巴喷丁凝胶制剂可提供理想的神经性疼痛缓解作用,而没有不受欢迎系统性副作用。 ud结论:这些结果提示使用CCI诱导的神经性疼痛模型,对局部加巴喷丁凝胶针对广泛的伤害性刺激 udmodals的有效性进行了药理学验证。他们还主张对某些神经性疼痛综合征进行局部加巴喷丁的进一步临床研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号